Kiniksa Pharmaceuticals International (KNSA) Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International's Receivables history runs 6 years deep, the most recent figure standing at $23.2 million for Q1 2026.

• Quarterly Receivables fell 42.03% year-over-year to $23.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.2 million (down 42.03% YoY) and the FY2025 annual result came in at $15.6 million, down 62.63% from the prior year.
• Receivables was $23.2 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $15.6 million in the prior quarter.
• Across five years, Receivables topped out at $51.7 million in Q3 2025 and bottomed at $3.0 million in Q3 2023.
• A 5-year average of $23.0 million and a median of $21.3 million in 2023 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables slumped 74.78% — and 2024, when it jumped 718.41%.
• Kiniksa Pharmaceuticals International's Receivables stood at $20.3 million in 2022, then grew by 4.68% to $21.3 million in 2023, then surged by 96.2% to $41.7 million in 2024, then tumbled by 62.63% to $15.6 million in 2025, then surged by 48.93% to $23.2 million in 2026.
• Business Quant data shows KNSA's Receivables at $23.2 million in Q1 2026, $15.6 million in Q4 2025, and $51.7 million in Q3 2025.